
Sign up to save your podcasts
Or


Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug's potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
By JAMA Network4.4
472472 ratings
Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug's potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.

321 Listeners

549 Listeners

701 Listeners

163 Listeners

260 Listeners

906 Listeners

3,374 Listeners

38 Listeners

21 Listeners

16 Listeners

11 Listeners

8 Listeners

17 Listeners

19 Listeners

5 Listeners

6 Listeners

1,150 Listeners

31 Listeners

9 Listeners

94 Listeners

141 Listeners

14 Listeners

5 Listeners

518 Listeners

5 Listeners

367 Listeners

260 Listeners

437 Listeners

106 Listeners

18 Listeners

320 Listeners

2 Listeners

325 Listeners

270 Listeners